FDA Approves Monthly Treatment Andembry for Hereditary Angioedema
The FDA has approved Andembry, a groundbreaking monthly injection for hereditary angioedema, offering effective prevention and improved quality of life for patients.
The U.S. Food and Drug Administration (FDA) has granted approval to Andembry (garadacimab-gxii), a novel medication designed for the prevention of hereditary angioedema (HAE) attacks. Notably, this medication is the first in its class that specifically targets factor XIIa, a key plasma protein involved in swelling episodes associated with HAE. Administration is convenient, with patients able to self-inject via an autoinjector in just 15 seconds, making it suitable for both adults and children aged 12 and older.
Hereditary angioedema is characterized by sudden, severe swelling typically affecting the face, throat, and extremities, often accompanied by symptoms such as swelling around eyes and cheeks, or lips, and mild pain. According to the Mayo Clinic, it manifests as deeper swelling of the skin, sometimes with hives, and can develop within minutes to hours.
The approval was based on results from a phase 3 clinical trial, wherein 62% of patients treated with Andembry experienced no attacks over six months. The medication demonstrated a median reduction of over 99% in HAE attacks compared to placebo, as well as significant decreases in attacks requiring on-demand treatment and moderate to severe attacks (both around 90-99%). Common side effects included nasal and upper throat inflammation, along with abdominal pain.
Bill Mezzanotte, M.D., CSL's head of research and development, highlighted that Andembry represents a groundbreaking advancement, offering individuals with HAE long-term disease management via a simple and effective method. CSL was the company granted approval for this innovative therapy.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Approach to Boost Brain Immunity Against HSV-1 by Targeting Viral Enzymes
Researchers at the University of Tokyo have developed a novel gene therapy targeting viral enzymes to reactivate the brain's natural immune defenses against HSV-1, opening new doors in treating deadly brain infections.
High-Resolution Insights into Metabolic Transitions from Fruit Fly Mothers to Embryos May Enhance Understanding of Human Development and Disease
A high-resolution study uncovers the detailed metabolic exchange from mother fruit flies to embryos, offering insights into human developmental health and diseases.
New Study Uncovers How Testosterone Influences Brain Function, Social Behavior, and Self-Worth in Young Men
Recent research from Hong Kong Polytechnic University reveals how testosterone influences brain function, social behavior, and self-esteem in young men, highlighting new potential for clinical applications.
Addressing the Hidden Burden of Chronic Pain in Australian Children
Chronic pain affects 1 in 5 Australian children, disrupting education, mental health, and family life. Recognizing it as a distinct condition is essential for better care and support.